Skip to main content

Table 4 Peak and trough concentration data and estimates of amikacin pharmacokinetic parameters

From: An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

Patient profile Dose Dosage interval Cpmax Cpmin t1/2 k TBC Vd
(mg) (h) (mg l-1) (mg l-1) (h) (h-1) (l h-1) (l)
P1A 900 24 31.3 3 6.80 0.102 2.858 28.03
P1B 900 24 33.8 4 7.63 0.091 2.583 28.44
P1C 1100 24 35.7 6.2 9.10 0.076 2.579 33.89
Mean      7.84 0.090 2.674 30.12
P2A 300 19 7.6 1.8 8.66 0.080 3.096 38.69
P2B 1500 24 50.2 2.8 5.52 0.125 3.761 29.97
P2C 1500 24 48.5 5.4 7.42 0.093 2.987 31.98
P2D 1500 29 49.4 5 8.47 0.082 2.719 33.24
P2E 1500 32 55.9 6.1 9.70 0.071 2.062 28.85
P2F 1500 29 53.8 7 9.51 0.073 2.239 30.74
Mean      8.21 0.088 2.811 32.25
CVVHDF Stopped P2G 1500 53.5 68.3 16.1 25.18 0.028 0.668 24.26
P3A 1500 24 44.9 2.8 5.74 0.121 3.911 32.42
P3B 1500 24 42.4 1.9 5.13 0.135 4.923 36.46
P3C 1500 24 46.5 2.1 5.26 0.132 4.278 32.46
Mean      5.38 0.129 4.371 33.78
P4A 600 12 16.2 4 5.45 0.127 4.563 35.88
P4B 600 12 23.4 5 5.16 0.134 3.961 29.52
Mean      5.31 0.131 4.262 32.70
P5A 1500 24 48.2 2.1 5.09 0.136 4.099 30.08
P5B 1500 25 52.4 2.4 5.39 0.128 3.701 28.81
P5C 1500 28 54.4 2.5 5.29 0.131 3.649 27.84
P5D 1500 28 55.8 2.5 6.03 0.115 3.137 27.28
Mean      5.45 0.128 3.646 28.50
Overall mean*      6.74 0.109 3.39 31.4
Standard deviation      1.69 0.025 0.82 3.27
Median      5.88 0.118 3.39 30.4
  1. * Excluding profile P2G.
  2. Cpmax: maximum serum concentration Cpmin: minimum serum concentration.
  3. t1/2: half life. Vd: volume of distribution. TBC: Total body clearance. k: elimination rate constant.
  4. PX (1–5): patients 1–5. PXA-PXE: first (A) to fifth (E) dosing interval during which serum concentration data was collected for patient PX.